Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres.
Ondrej ŠušolBarbora HájkováHana ZelenáRoman HájekPublished in: British journal of haematology (2022)
We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an overall antibody response of 70% (best in cMPN, worst in CLL). We have then vaccinated 80 patients who did not achieve seroconversion or were low responders with a third dose of COMIRNATY vaccine. Our first results show promise, especially for patients on anti-CD38 therapy.